A number of selective inhibitors of the TEAD family members are in development and have been shown to disrupt YAP1/WWTR1/TEAD-dependent transcription, affect the viability of NF2 mutant mesothelioma models, and to enhance the efficacy of EGFR inhibitors in EGFR mutant lung cancer5,16,22. This evidence concerns the gene YAP1 and mesothelioma.